Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]
Tumor-infiltrating lymphocytes (TILs) are a robust and independent prognostic variable in localized colon cancer. Given reported differences in molecular features and prognosis of right- versus left-sided tumors, we examined the association of TIL densities with patient survival by primary tumor sid...
Gespeichert in:
Veröffentlicht in: | Annals of oncology 2022-11, Vol.33 (11), p.1159-1167 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1167 |
---|---|
container_issue | 11 |
container_start_page | 1159 |
container_title | Annals of oncology |
container_volume | 33 |
creator | Saberzadeh-Ardestani, B. Foster, N.R. Lee, H.E. Shi, Q. Alberts, S.R. Smyrk, T.C. Sinicrope, F.A. |
description | Tumor-infiltrating lymphocytes (TILs) are a robust and independent prognostic variable in localized colon cancer. Given reported differences in molecular features and prognosis of right- versus left-sided tumors, we examined the association of TIL densities with patient survival by primary tumor sidedness in stage III cancers, including clinical low- (T1-3, N1) and high-risk (T4 and/or N2) groups.
In a phase III trial of FOLFOX-based adjuvant chemotherapy, TIL densities were analyzed and dichotomized in colon carcinomas (N = 1532) based on a previously determined cut point optimized for disease-free survival (DFS). Right-sided tumors were defined as proximal to the splenic flexure. Associations of TILs and sidedness with 5-year DFS were examined using Kaplan–Meier methodology along with multivariable modeling and relative contribution analysis by Cox regression.
Lower TIL densities were found in left- versus right-sided tumors (P < 0.0001). The association of TIL densities with DFS differed significantly by tumor sidedness (Pinteraction = 0.045). Overall, patient tumors with low (versus high) TILs had significantly poorer DFS in right-sided (hazard ratio 2.02, 95% confidence interval 1.45-2.82; Padj < 0.0001), but not left-sided tumors (Padj = 0.1731). Among clinical low-risk patients, low (versus high) TILs were adversely prognostic only in right-sided tumors (Padj = 0.0058). Among high-risk patients, low TILs were prognostic independent of sidedness (Padj < 0.025). The relative contribution of TILs to DFS was substantially greater in right- versus left-sided tumors (24% versus 1.5%). In high-risk tumors, TILs had the highest relative contribution to DFS (42%) of all variables. In low-risk tumors, the contribution of TILs (16%) to DFS was second to KRAS.
The association of TIL densities with patient survival differed by primary tumor sidedness and clinical risk group, suggesting that TILs should be interpreted in this context among stage III colon cancers.
NCT00079274; https://clinicaltrials.gov/ct2/show/NCT00079274
•Association of TIL densities with 5-year DFS differed significantly by primary tumor sidedness.•Overall, low versus high TILs were significantly associated with poorer DFS among right-sided, but not left-sided tumors.•Prognostic impact of TILs was limited to right-sided cancers among clinical low-risk tumors.•Relative contribution of TILs to DFS was greater in right- versus left-sided tumors (24% versus 1.5%).•In clinical high-risk tumors, TI |
doi_str_mv | 10.1016/j.annonc.2022.07.1942 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9882989</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753422037942</els_id><sourcerecordid>2702186947</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-fb45e854fbd0094c76ccf72247dbb74d9afee1e2d6c9a558a83b1334ffa3013d3</originalsourceid><addsrcrecordid>eNqFkc2O0zAUhS0EYsrAI4C8HBYJ_kscb0BVBUOl0bAZVghZjn3TukrtYidFfQ2emFQpI1ixsuR7zrk_H0KvKSkpofW7XWlCiMGWjDBWEllSJdgTtKBVrYqGCPoULYhivJAVF1foRc47QkitmHqOrnilai4askC_ljlH683gY8Cxw8O4j6nwofP9kKbfsMH9aX_YRnsaIOOfftjiPKajP5oeOzhAcBlP1kPye5NOsx9n78AFyBn7gPNgNoDX6zW2sZ-k1gQLKeOb-9Xq4RbfEyrkW_xt2ff-XPn-Ej3rTJ_h1eW9Rl8_fXxYfS7uvtyuV8u7wopaDkXXigqaSnStI0QJK2trO8mYkK5tpXDKdAAUmKutMlXVmIa3lHPRdYYTyh2_Ru_n3MPY7sFZCNPGvb5soqPx-t9K8Fu9iUetmoapRk0BN5eAFH-MkAe999lC35sAccyaScJoUyshJ2k1S22KOSfoHttQos889U7PPPWZpyZSn3lOvjd_z_jo-gNwEnyYBTBd6ugh6Ww9TGd0PoEdtIv-Py1-A3set4g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2702186947</pqid></control><display><type>article</type><title>Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Saberzadeh-Ardestani, B. ; Foster, N.R. ; Lee, H.E. ; Shi, Q. ; Alberts, S.R. ; Smyrk, T.C. ; Sinicrope, F.A.</creator><creatorcontrib>Saberzadeh-Ardestani, B. ; Foster, N.R. ; Lee, H.E. ; Shi, Q. ; Alberts, S.R. ; Smyrk, T.C. ; Sinicrope, F.A.</creatorcontrib><description>Tumor-infiltrating lymphocytes (TILs) are a robust and independent prognostic variable in localized colon cancer. Given reported differences in molecular features and prognosis of right- versus left-sided tumors, we examined the association of TIL densities with patient survival by primary tumor sidedness in stage III cancers, including clinical low- (T1-3, N1) and high-risk (T4 and/or N2) groups.
In a phase III trial of FOLFOX-based adjuvant chemotherapy, TIL densities were analyzed and dichotomized in colon carcinomas (N = 1532) based on a previously determined cut point optimized for disease-free survival (DFS). Right-sided tumors were defined as proximal to the splenic flexure. Associations of TILs and sidedness with 5-year DFS were examined using Kaplan–Meier methodology along with multivariable modeling and relative contribution analysis by Cox regression.
Lower TIL densities were found in left- versus right-sided tumors (P < 0.0001). The association of TIL densities with DFS differed significantly by tumor sidedness (Pinteraction = 0.045). Overall, patient tumors with low (versus high) TILs had significantly poorer DFS in right-sided (hazard ratio 2.02, 95% confidence interval 1.45-2.82; Padj < 0.0001), but not left-sided tumors (Padj = 0.1731). Among clinical low-risk patients, low (versus high) TILs were adversely prognostic only in right-sided tumors (Padj = 0.0058). Among high-risk patients, low TILs were prognostic independent of sidedness (Padj < 0.025). The relative contribution of TILs to DFS was substantially greater in right- versus left-sided tumors (24% versus 1.5%). In high-risk tumors, TILs had the highest relative contribution to DFS (42%) of all variables. In low-risk tumors, the contribution of TILs (16%) to DFS was second to KRAS.
The association of TIL densities with patient survival differed by primary tumor sidedness and clinical risk group, suggesting that TILs should be interpreted in this context among stage III colon cancers.
NCT00079274; https://clinicaltrials.gov/ct2/show/NCT00079274
•Association of TIL densities with 5-year DFS differed significantly by primary tumor sidedness.•Overall, low versus high TILs were significantly associated with poorer DFS among right-sided, but not left-sided tumors.•Prognostic impact of TILs was limited to right-sided cancers among clinical low-risk tumors.•Relative contribution of TILs to DFS was greater in right- versus left-sided tumors (24% versus 1.5%).•In clinical high-risk tumors, TILs had the highest relative contribution to DFS of all variables.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1016/j.annonc.2022.07.1942</identifier><identifier>PMID: 35963480</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>adjuvant chemotherapy ; Chemotherapy, Adjuvant ; colonic neoplasms ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - genetics ; Disease-Free Survival ; Humans ; Lymphocytes, Tumor-Infiltrating - pathology ; Neoplasm Staging ; primary tumor site ; Prognosis ; tumor-infiltrating lymphocytes</subject><ispartof>Annals of oncology, 2022-11, Vol.33 (11), p.1159-1167</ispartof><rights>2022 European Society for Medical Oncology</rights><rights>Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-fb45e854fbd0094c76ccf72247dbb74d9afee1e2d6c9a558a83b1334ffa3013d3</citedby><cites>FETCH-LOGICAL-c467t-fb45e854fbd0094c76ccf72247dbb74d9afee1e2d6c9a558a83b1334ffa3013d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35963480$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saberzadeh-Ardestani, B.</creatorcontrib><creatorcontrib>Foster, N.R.</creatorcontrib><creatorcontrib>Lee, H.E.</creatorcontrib><creatorcontrib>Shi, Q.</creatorcontrib><creatorcontrib>Alberts, S.R.</creatorcontrib><creatorcontrib>Smyrk, T.C.</creatorcontrib><creatorcontrib>Sinicrope, F.A.</creatorcontrib><title>Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Tumor-infiltrating lymphocytes (TILs) are a robust and independent prognostic variable in localized colon cancer. Given reported differences in molecular features and prognosis of right- versus left-sided tumors, we examined the association of TIL densities with patient survival by primary tumor sidedness in stage III cancers, including clinical low- (T1-3, N1) and high-risk (T4 and/or N2) groups.
In a phase III trial of FOLFOX-based adjuvant chemotherapy, TIL densities were analyzed and dichotomized in colon carcinomas (N = 1532) based on a previously determined cut point optimized for disease-free survival (DFS). Right-sided tumors were defined as proximal to the splenic flexure. Associations of TILs and sidedness with 5-year DFS were examined using Kaplan–Meier methodology along with multivariable modeling and relative contribution analysis by Cox regression.
Lower TIL densities were found in left- versus right-sided tumors (P < 0.0001). The association of TIL densities with DFS differed significantly by tumor sidedness (Pinteraction = 0.045). Overall, patient tumors with low (versus high) TILs had significantly poorer DFS in right-sided (hazard ratio 2.02, 95% confidence interval 1.45-2.82; Padj < 0.0001), but not left-sided tumors (Padj = 0.1731). Among clinical low-risk patients, low (versus high) TILs were adversely prognostic only in right-sided tumors (Padj = 0.0058). Among high-risk patients, low TILs were prognostic independent of sidedness (Padj < 0.025). The relative contribution of TILs to DFS was substantially greater in right- versus left-sided tumors (24% versus 1.5%). In high-risk tumors, TILs had the highest relative contribution to DFS (42%) of all variables. In low-risk tumors, the contribution of TILs (16%) to DFS was second to KRAS.
The association of TIL densities with patient survival differed by primary tumor sidedness and clinical risk group, suggesting that TILs should be interpreted in this context among stage III colon cancers.
NCT00079274; https://clinicaltrials.gov/ct2/show/NCT00079274
•Association of TIL densities with 5-year DFS differed significantly by primary tumor sidedness.•Overall, low versus high TILs were significantly associated with poorer DFS among right-sided, but not left-sided tumors.•Prognostic impact of TILs was limited to right-sided cancers among clinical low-risk tumors.•Relative contribution of TILs to DFS was greater in right- versus left-sided tumors (24% versus 1.5%).•In clinical high-risk tumors, TILs had the highest relative contribution to DFS of all variables.</description><subject>adjuvant chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>colonic neoplasms</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - genetics</subject><subject>Disease-Free Survival</subject><subject>Humans</subject><subject>Lymphocytes, Tumor-Infiltrating - pathology</subject><subject>Neoplasm Staging</subject><subject>primary tumor site</subject><subject>Prognosis</subject><subject>tumor-infiltrating lymphocytes</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2O0zAUhS0EYsrAI4C8HBYJ_kscb0BVBUOl0bAZVghZjn3TukrtYidFfQ2emFQpI1ixsuR7zrk_H0KvKSkpofW7XWlCiMGWjDBWEllSJdgTtKBVrYqGCPoULYhivJAVF1foRc47QkitmHqOrnilai4askC_ljlH683gY8Cxw8O4j6nwofP9kKbfsMH9aX_YRnsaIOOfftjiPKajP5oeOzhAcBlP1kPye5NOsx9n78AFyBn7gPNgNoDX6zW2sZ-k1gQLKeOb-9Xq4RbfEyrkW_xt2ff-XPn-Ej3rTJ_h1eW9Rl8_fXxYfS7uvtyuV8u7wopaDkXXigqaSnStI0QJK2trO8mYkK5tpXDKdAAUmKutMlXVmIa3lHPRdYYTyh2_Ru_n3MPY7sFZCNPGvb5soqPx-t9K8Fu9iUetmoapRk0BN5eAFH-MkAe999lC35sAccyaScJoUyshJ2k1S22KOSfoHttQos889U7PPPWZpyZSn3lOvjd_z_jo-gNwEnyYBTBd6ugh6Ww9TGd0PoEdtIv-Py1-A3set4g</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Saberzadeh-Ardestani, B.</creator><creator>Foster, N.R.</creator><creator>Lee, H.E.</creator><creator>Shi, Q.</creator><creator>Alberts, S.R.</creator><creator>Smyrk, T.C.</creator><creator>Sinicrope, F.A.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221101</creationdate><title>Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]</title><author>Saberzadeh-Ardestani, B. ; Foster, N.R. ; Lee, H.E. ; Shi, Q. ; Alberts, S.R. ; Smyrk, T.C. ; Sinicrope, F.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-fb45e854fbd0094c76ccf72247dbb74d9afee1e2d6c9a558a83b1334ffa3013d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>adjuvant chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>colonic neoplasms</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - genetics</topic><topic>Disease-Free Survival</topic><topic>Humans</topic><topic>Lymphocytes, Tumor-Infiltrating - pathology</topic><topic>Neoplasm Staging</topic><topic>primary tumor site</topic><topic>Prognosis</topic><topic>tumor-infiltrating lymphocytes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saberzadeh-Ardestani, B.</creatorcontrib><creatorcontrib>Foster, N.R.</creatorcontrib><creatorcontrib>Lee, H.E.</creatorcontrib><creatorcontrib>Shi, Q.</creatorcontrib><creatorcontrib>Alberts, S.R.</creatorcontrib><creatorcontrib>Smyrk, T.C.</creatorcontrib><creatorcontrib>Sinicrope, F.A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saberzadeh-Ardestani, B.</au><au>Foster, N.R.</au><au>Lee, H.E.</au><au>Shi, Q.</au><au>Alberts, S.R.</au><au>Smyrk, T.C.</au><au>Sinicrope, F.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>33</volume><issue>11</issue><spage>1159</spage><epage>1167</epage><pages>1159-1167</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Tumor-infiltrating lymphocytes (TILs) are a robust and independent prognostic variable in localized colon cancer. Given reported differences in molecular features and prognosis of right- versus left-sided tumors, we examined the association of TIL densities with patient survival by primary tumor sidedness in stage III cancers, including clinical low- (T1-3, N1) and high-risk (T4 and/or N2) groups.
In a phase III trial of FOLFOX-based adjuvant chemotherapy, TIL densities were analyzed and dichotomized in colon carcinomas (N = 1532) based on a previously determined cut point optimized for disease-free survival (DFS). Right-sided tumors were defined as proximal to the splenic flexure. Associations of TILs and sidedness with 5-year DFS were examined using Kaplan–Meier methodology along with multivariable modeling and relative contribution analysis by Cox regression.
Lower TIL densities were found in left- versus right-sided tumors (P < 0.0001). The association of TIL densities with DFS differed significantly by tumor sidedness (Pinteraction = 0.045). Overall, patient tumors with low (versus high) TILs had significantly poorer DFS in right-sided (hazard ratio 2.02, 95% confidence interval 1.45-2.82; Padj < 0.0001), but not left-sided tumors (Padj = 0.1731). Among clinical low-risk patients, low (versus high) TILs were adversely prognostic only in right-sided tumors (Padj = 0.0058). Among high-risk patients, low TILs were prognostic independent of sidedness (Padj < 0.025). The relative contribution of TILs to DFS was substantially greater in right- versus left-sided tumors (24% versus 1.5%). In high-risk tumors, TILs had the highest relative contribution to DFS (42%) of all variables. In low-risk tumors, the contribution of TILs (16%) to DFS was second to KRAS.
The association of TIL densities with patient survival differed by primary tumor sidedness and clinical risk group, suggesting that TILs should be interpreted in this context among stage III colon cancers.
NCT00079274; https://clinicaltrials.gov/ct2/show/NCT00079274
•Association of TIL densities with 5-year DFS differed significantly by primary tumor sidedness.•Overall, low versus high TILs were significantly associated with poorer DFS among right-sided, but not left-sided tumors.•Prognostic impact of TILs was limited to right-sided cancers among clinical low-risk tumors.•Relative contribution of TILs to DFS was greater in right- versus left-sided tumors (24% versus 1.5%).•In clinical high-risk tumors, TILs had the highest relative contribution to DFS of all variables.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>35963480</pmid><doi>10.1016/j.annonc.2022.07.1942</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0923-7534 |
ispartof | Annals of oncology, 2022-11, Vol.33 (11), p.1159-1167 |
issn | 0923-7534 1569-8041 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9882989 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | adjuvant chemotherapy Chemotherapy, Adjuvant colonic neoplasms Colonic Neoplasms - drug therapy Colonic Neoplasms - genetics Disease-Free Survival Humans Lymphocytes, Tumor-Infiltrating - pathology Neoplasm Staging primary tumor site Prognosis tumor-infiltrating lymphocytes |
title | Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance] |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T23%3A41%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20tumor-infiltrating%20lymphocytes%20with%20survival%20depends%20on%20primary%20tumor%20sidedness%20in%20stage%20III%20colon%20cancers%20(NCCTG%20N0147)%20%5BAlliance%5D&rft.jtitle=Annals%20of%20oncology&rft.au=Saberzadeh-Ardestani,%20B.&rft.date=2022-11-01&rft.volume=33&rft.issue=11&rft.spage=1159&rft.epage=1167&rft.pages=1159-1167&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1016/j.annonc.2022.07.1942&rft_dat=%3Cproquest_pubme%3E2702186947%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2702186947&rft_id=info:pmid/35963480&rft_els_id=S0923753422037942&rfr_iscdi=true |